These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32279953)

  • 1. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review.
    Carando R; Pradere B; Afferi L; Marra G; Aziz A; Roghmann F; Krajewski W; Di Bona C; Alvarez-Maestro M; Pagliarulo V; Xylinas E; Moschini M
    Prog Urol; 2020 May; 30(6):322-331. PubMed ID: 32279953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
    Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer.
    Tan WS; Kelly JD
    Nat Rev Urol; 2018 Nov; 15(11):667-685. PubMed ID: 30254383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
    Pierconti F; Straccia P; Emilio S; Bassi PF; De Pascalis I; Marques RC; Volavsek M; Larocca LM; Lopez-Beltran A
    Pathol Res Pract; 2017 Sep; 213(9):1078-1081. PubMed ID: 28843746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
    Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Riedl C
    World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
    Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD
    Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical therapy with mitomycin through electromotive drug administration].
    Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
    Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
    Busetto GM; Finati M; Chirico M; Cinelli F; D'Altilia N; Falagario UG; Sanguedolce F; Del Giudice F; De Berardinis E; Ferro M; Crocetto F; Porreca A; Di Gianfrancesco L; Calo' B; Mancini V; Bettocchi C; Carrieri G; Cormio L
    World J Urol; 2023 May; 41(5):1329-1335. PubMed ID: 36971825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer.
    Slater SE; Patel P; Viney R; Foster M; Porfiri E; James ND; Montgomery B; Bryan RT
    Ann R Coll Surg Engl; 2014 Sep; 96(6):415-9. PubMed ID: 25198970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).
    Álvarez-Maestro M; Guerrero-Ramos F; Rodríguez-Faba O; Domínguez-Escrig JL; Fernández-Gómez JM
    Actas Urol Esp (Engl Ed); 2021 Mar; 45(2):93-102. PubMed ID: 33012593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical Chemotherapy and Chemohyperthermia in Non-Muscle-Invasive Bladder Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics.
    Campodonico F; Di Stasi S; Lev GM; Terrone C; Bongiovanni L; Mattioli F; Pagliarulo V; Introini C
    Curr Drug Metab; 2017; 18(7):657-665. PubMed ID: 28460622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.